CA Patent

CA2683409A1 — A pharmaceutical composition of tacrolimus

Assigned to Sigmoid Pharma Ltd · Expires 2008-10-16 · 18y expired

What this patent protects

An oral tacrolimus composition comprises minicapsules having a core containing tacrolimus in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised tacrolimus throughout the entire gastrointestinal tract. The composition may be used, for…

USPTO Abstract

An oral tacrolimus composition comprises minicapsules having a core containing tacrolimus in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised tacrolimus throughout the entire gastrointestinal tract. The composition may be used, for example, for treatment or prevention of solid organ transplant rejection.

Drugs covered by this patent

methylphenidate-hydrochloride (METHYLPHENIDATE HYDROCHLORIDE)

Patent Metadata

Patent number: CA2683409A1
Jurisdiction: CA
Classification: —
Expires: 2008-10-16
Drug substance claim: No
Drug product claim: No
Assignee: Sigmoid Pharma Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.